{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:05:54Z","timestamp":1793203554640,"version":"4.5.0"},"reference-count":68,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Concomitant obesity is common among patients with type 1 diabetes mellitus (T1DM), yet adjunctive therapy options are scarce.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We assess the efficacy and adverse outcomes of glucagon-like peptide 1 (GLP-1) analogues when used as adjunctive therapy for T1DM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Method<\/jats:title>\n                  <jats:p>PubMed, EMBASE, Cochrane Central, and Scopus databases were searched for randomized controlled trials up to December 2022. Efficacy outcomes were A1c level, body weight, and total daily insulin (TDI) after \u226512 weeks of GLP-1 therapy. We also assessed 12 different adverse outcomes. Subgroup analysis was done for newly diagnosed or C-peptide positive (C-pos) patients. We report the certainty of evidence based on the GRADE assessment tool.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 24 studies using 4 different GLP-1 analogues with a total of 3377 patients were included. Liraglutide had the most substantial evidence with effect sizes on A1c (\u22120.09%\/mg), weight (\u22122.2 kg\/mg), and TDI (\u22124.32 IU\/mg). Liraglutide dose was the greatest predictor of greater average weight loss and TDI decrease but was associated with higher odds of nausea (OR 6.5; 95% CI, 5.0-8.4) and ketosis (OR 1.8; 95% CI, 1.1-2.8). Odds of severe (OR 0.67; 95% CI, 0.43-1.04) or symptomatic hypoglycemia (OR 0.89; 95% CI, 0.53-1.51) were not significantly elevated. Among C-pos patients, greater A1c decrease (\u22120.51% vs \u22120.28%) but similar weight loss and TDI were seen. Effect sizes for exenatide were similar, but studies had higher risk of bias and safety data were sparse.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our meta-analysis supports therapeutic benefits of liraglutide for patients with T1DM mainly for weight loss and insulin dose reduction. Newly diagnosed or C-pos patients do not appear to experience greater weight loss benefits.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgad471","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T14:10:22Z","timestamp":1691676622000},"page":"279-292","source":"Crossref","is-referenced-by-count":70,"title":["Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis"],"prefix":"10.1210","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5812-1038","authenticated-orcid":false,"given":"Jeayoung","family":"Park","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine , Baltimore, MD 21201 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Ntelis","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine , Baltimore, MD 21201 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvina","family":"Yunasan","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine , Baltimore, MD 21201 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine D","family":"Downton","sequence":"additional","affiliation":[{"name":"Health Sciences and Human Services Library, University of Maryland , Baltimore, MD 21201 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1819-2464","authenticated-orcid":false,"given":"Terry Cheuk-Fung","family":"Yip","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics, The Chinese University of Hong Kong , Central Ave , Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1075-1284","authenticated-orcid":false,"given":"Kashif M","family":"Munir","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine , Baltimore, MD 21201 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0659-2249","authenticated-orcid":false,"given":"Nowreen","family":"Haq","sequence":"additional","affiliation":[{"name":"Lead Endocrinologist, Diabetes and Obesity Management Clinic, Chase Brexton Healthcare , Baltimore, MD 21201 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"issue":"12","key":"2023122122202465000_dgad471-B1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S2213-8587(20)30337-5","article-title":"Insulin's centenary: the birth of an idea","volume":"8","author":"Hegele","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2023122122202465000_dgad471-B2","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.2337\/dc15-1037","article-title":"Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double-blind parallel study","volume":"38","author":"Frandsen","year":"2015","journal-title":"Diabetes Care"},{"issue":"8","key":"2023122122202465000_dgad471-B3","doi-asserted-by":"crossref","first-page":"e142242","DOI":"10.1172\/JCI142242","article-title":"Type 1 diabetes mellitus: much progress, many opportunities","volume":"131","author":"Powers","year":"2021","journal-title":"J Clin Invest"},{"issue":"4","key":"2023122122202465000_dgad471-B4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/dom.13911","article-title":"Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: the Lira Pump trial\u2014a randomized, double-blinded, placebo-controlled trial","volume":"22","author":"Dejgaard","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"21","key":"2023122122202465000_dgad471-B5","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa1408214","article-title":"Glycemic control and excess mortality in type 1 diabetes","volume":"371","author":"Lind","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"2023122122202465000_dgad471-B6","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(21)00246-1","article-title":"Obesity in people living with type 1 diabetes","volume":"9","author":"Van der Schueren","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"2023122122202465000_dgad471-B7","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2337\/dc16-0690","article-title":"Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial","volume":"39","author":"Ahr\u00e9n","year":"2016","journal-title":"Diabetes Care"},{"issue":"Suppl 3","key":"2023122122202465000_dgad471-B8","first-page":"111S","article-title":"Use of pramlintide: the patient's Perspective","volume":"32","author":"Want","year":"2006","journal-title":"Diabetes Educ"},{"key":"2023122122202465000_dgad471-B9","doi-asserted-by":"crossref","first-page":"o373","DOI":"10.1136\/bmj.o373","article-title":"Type 1 diabetes drug was withdrawn because of a \u201ccommercial conflict of interest,\u201d charity argues","volume":"376","author":"Mahase","year":"2022","journal-title":"BMJ"},{"issue":"11","key":"2023122122202465000_dgad471-B10","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1111\/bcp.14063","article-title":"Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy","volume":"85","author":"Brock","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 1","key":"2023122122202465000_dgad471-B11","doi-asserted-by":"crossref","first-page":"3-LB","DOI":"10.2337\/db18-3-LB","article-title":"Liraglutide as an additional treatment to insulin in patients with type 1 diabetes mellitus\u2014a 52-week randomized double-blinded placebo-controlled clinical trial","volume":"67","author":"Dandona","year":"2018","journal-title":"Diabetes"},{"issue":"3","key":"2023122122202465000_dgad471-B12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(15)00436-2","article-title":"Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial","volume":"4","author":"Dejgaard","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 1","key":"2023122122202465000_dgad471-B13","doi-asserted-by":"crossref","first-page":"59-OR","DOI":"10.2337\/db19-59-OR","article-title":"59-OR: Liraglutide preserved insulin secretion in adults with newly diagnosed type 1 diabetes: the NewLira trial","volume":"68","author":"Dejgaard","year":"2019","journal-title":"Diabetes"},{"issue":"8","key":"2023122122202465000_dgad471-B14","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/dom.14050","article-title":"Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight people with type 1 diabetes","volume":"22","author":"Dub\u00e9","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2023122122202465000_dgad471-B15","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1111\/dom.14090","article-title":"Liraglutide treatment in overweight and obese patients with type 1 diabetes: a 26-week randomized controlled trial; mechanisms of weight loss","volume":"22","author":"Ghanim","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"2023122122202465000_dgad471-B16","first-page":"S7","article-title":"Abstracts of the 48th EASD (European Association for the Study of Diabetes) annual meeting of the European Association for the Study of Diabetes. October 1-5, 2012. Berlin, Germany","volume":"55","year":"2012","journal-title":"Diabetologia"},{"issue":"2","key":"2023122122202465000_dgad471-B17","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.diabres.2013.01.020","article-title":"Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: A randomized, open label study","volume":"100","author":"Hari Kumar","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"2023122122202465000_dgad471-B18","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1111\/dom.14121","article-title":"Exenatide extended release in patients with type 1 diabetes with and without residual insulin production","volume":"22","author":"Herold","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2023122122202465000_dgad471-B19","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(20)30030-9","article-title":"Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial","volume":"8","author":"Johansen","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2023122122202465000_dgad471-B20","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2337\/dc15-1136","article-title":"Addition of liraglutide to insulin in patients with type 1 diabetes: a randomized placebo-controlled clinical trial of 12 weeks","volume":"39","author":"Kuhadiya","year":"2016","journal-title":"Diabetes Care"},{"issue":"10","key":"2023122122202465000_dgad471-B21","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.2337\/dc16-0691","article-title":"Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial","volume":"39","author":"Mathieu","year":"2016","journal-title":"Diabetes Care"},{"issue":"6","key":"2023122122202465000_dgad471-B22","doi-asserted-by":"crossref","first-page":"e2192","DOI":"10.1210\/clinem\/dgaa149","article-title":"Randomized 52-week phase 2 trial of albiglutide versus placebo in adult patients with newly diagnosed type 1 diabetes","volume":"105","author":"Pozzilli","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2023122122202465000_dgad471-B23","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.2337\/dc09-0773","article-title":"Effects of exenatide alone and in combination with daclizumab on (-cell function in long-standing type 1 diabetes","volume":"32","author":"Rother","year":"2009","journal-title":"Diabetes Care"},{"issue":"3","key":"2023122122202465000_dgad471-B24","doi-asserted-by":"crossref","first-page":"666","DOI":"10.2337\/dc13-1473","article-title":"Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes","volume":"37","author":"Sarkar","year":"2014","journal-title":"Diabetes Care"},{"issue":"4","key":"2023122122202465000_dgad471-B25","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S2213-8587(21)00019-X","article-title":"Anti-interleukin-21 antibody and liraglutide for the preservation of (-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"von Herrath","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2023122122202465000_dgad471-B26","doi-asserted-by":"crossref","first-page":"e3583","DOI":"10.1210\/clinem\/dgac369","article-title":"Effect of liraglutide treatment on whole-body glucose fluxes in C-peptide\u2013positive type 1 diabetes during hypoglycemia","volume":"107","author":"Zenz","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023122122202465000_dgad471-B27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.metabol.2013.09.010","article-title":"Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells","volume":"63","author":"Lee","year":"2014","journal-title":"Metabolism"},{"issue":"8","key":"2023122122202465000_dgad471-B28","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/1060028016651279","article-title":"GLP-1 agonists in type 1 diabetes mellitus","volume":"50","author":"Janzen","year":"2016","journal-title":"Ann Pharmacother"},{"issue":"4","key":"2023122122202465000_dgad471-B29","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s13300-017-0282-3","article-title":"Effects of insulin plus glucagon-like peptide-1 receptor agonists (GLP-1RAs) in treating type 1 diabetes mellitus: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Diabetes Ther"},{"issue":"3","key":"2023122122202465000_dgad471-B30","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/dom.14291","article-title":"Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: a systematic review and network meta-analysis","volume":"23","author":"Avgerinos","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2023122122202465000_dgad471-B31","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3389\/fendo.2020.00553","article-title":"Effects of sodium-glucose cotransporter inhibitor\/glucagon-like peptide-1 receptor agonist add-on to insulin therapy on glucose homeostasis and body weight in patients with type 1 diabetes: a network meta-analysis","volume":"11","author":"Kim","year":"2020","journal-title":"Front Endocrinol"},{"issue":"2","key":"2023122122202465000_dgad471-B32","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/dom.14221","article-title":"The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: a systematic review and meta-analysis","volume":"23","author":"Tandon","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2023122122202465000_dgad471-B33","first-page":"313","article-title":"Liraglutide as Adjunct to insulin treatment in patients with type 1 diabetes: a systematic review and meta-analysis","volume":"16","author":"Dimitrios","year":"2020","journal-title":"Curr Diabetes Rev"},{"issue":"6","key":"2023122122202465000_dgad471-B34","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab"},{"issue":"11","key":"2023122122202465000_dgad471-B35","first-page":"CD013164","article-title":"Glucagon-like peptide (GLP)-1 analogues as an add-on to insulin for adults with type 1 diabetes mellitus","volume":"2018","author":"Yamada","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2023122122202465000_dgad471-B36","author":"Park"},{"key":"2023122122202465000_dgad471-B37","author":"Higgins"},{"issue":"7109","key":"2023122122202465000_dgad471-B38","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"20","key":"2023122122202465000_dgad471-B39","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V","article-title":"Explaining heterogeneity in meta-analysis: a comparison of methods","volume":"18","author":"Thompson","year":"1999","journal-title":"Stat Med"},{"issue":"3","key":"2023122122202465000_dgad471-B40","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis: quantifying publication bias","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics"},{"issue":"20","key":"2023122122202465000_dgad471-B41","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Stat Med"},{"key":"2023122122202465000_dgad471-B42","volume-title":"GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations","author":"Sch\u00fcnemann","year":"2013"},{"key":"2023122122202465000_dgad471-B43"},{"issue":"4","key":"2023122122202465000_dgad471-B44","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/jrsm.1489","article-title":"Using information-theoretic approaches for model selection in meta-analysis","volume":"12","author":"Cinar","year":"2021","journal-title":"Res Synth Methods"},{"key":"2023122122202465000_dgad471-B45","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1201\/9781003107347","volume-title":"Doing Meta-Analysis with R: A Hands-on Guide","author":"Harrer","year":"2021"},{"issue":"9","key":"2023122122202465000_dgad471-B46","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1210\/jc.2016-1451","article-title":"Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes","volume":"101","author":"Kuhadiya","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023122122202465000_dgad471-B47","doi-asserted-by":"crossref","first-page":"e00130","DOI":"10.1002\/edm2.130","article-title":"Lixisenatide in type 1 diabetes: a randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients","volume":"3","author":"Ballav","year":"2020","journal-title":"Endocrinol Diabetes Metab"},{"issue":"7","key":"2023122122202465000_dgad471-B48","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2337\/dc11-0096","article-title":"Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual \u03b2-cell function","volume":"34","author":"Kielgast","year":"2011","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"2023122122202465000_dgad471-B49","first-page":"A258","article-title":"Liraglutide as adjunct to insulin in type 1 diabetes: effects on glycemic control and safety in a randomized, double-blind, crossover trial","volume":"62","author":"Heller","year":"2013","journal-title":"Diabetes"},{"issue":"5","key":"2023122122202465000_dgad471-B50","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s40618-017-0765-0","article-title":"The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus","volume":"41","author":"Jiang","year":"2018","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"2023122122202465000_dgad471-B51","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1210\/jc.2019-00087","article-title":"Effect of the GLP-1 receptor agonist exenatide on impaired awareness of hypoglycemia in type 1 diabetes: a randomized controlled trial","volume":"104","author":"van Meijel","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023122122202465000_dgad471-B52","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.2337\/dc12-2480","article-title":"Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and The Endocrine Society","volume":"36","author":"Seaquist","year":"2013","journal-title":"Diabetes Care"},{"issue":"1","key":"2023122122202465000_dgad471-B53","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"2023122122202465000_dgad471-B54","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1517\/14712598.2016.1160050","article-title":"Liraglutide for treating type 1 diabetes","volume":"16","author":"Dejgaard","year":"2016","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"2023122122202465000_dgad471-B55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"2023122122202465000_dgad471-B56","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"issue":"12","key":"2023122122202465000_dgad471-B57","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1111\/dom.14532","article-title":"Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials","volume":"23","author":"Dejgaard","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"2023122122202465000_dgad471-B58","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1080\/14656566.2018.1519547","article-title":"Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes?","volume":"19","author":"Doggrell","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"2023122122202465000_dgad471-B59","doi-asserted-by":"crossref","first-page":"997578","DOI":"10.3389\/fimmu.2022.997578","article-title":"GLP-1 receptor agonist as a modulator of innate immunity","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"2023122122202465000_dgad471-B60","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab"},{"issue":"8","key":"2023122122202465000_dgad471-B61","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1056\/NEJMoa2003697","article-title":"Effects of diet versus gastric bypass on metabolic function in diabetes","volume":"383","author":"Yoshino","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"2023122122202465000_dgad471-B62","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.2337\/dbi20-0048","article-title":"Targeting the pancreatic \u03b1-cell to prevent hypoglycemia in type 1 diabetes","volume":"70","author":"Panzer","year":"2021","journal-title":"Diabetes"},{"issue":"3","key":"2023122122202465000_dgad471-B63","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ecl.2010.05.003","article-title":"Hypoglycemia in type 1 diabetes mellitus","volume":"39","author":"Cryer","year":"2010","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"8","key":"2023122122202465000_dgad471-B64","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/dom.12473","article-title":"Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial","volume":"17","author":"Pieber","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2023122122202465000_dgad471-B65","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.numecd.2021.10.003","article-title":"The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system","volume":"32","author":"Yang","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"12","key":"2023122122202465000_dgad471-B66","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/2041-210X.12835","article-title":"A farewell to the sum of Akaike weights: the benefits of alternative metrics for variable importance estimations in model selection","volume":"8","author":"Galipaud","year":"2017","journal-title":"Methods Ecol Evol"},{"issue":"10","key":"2023122122202465000_dgad471-B67","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"2023122122202465000_dgad471-B68","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad471\/51283440\/dgad471.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/1\/279\/54731659\/dgad471.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/1\/279\/54731659\/dgad471.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T22:22:30Z","timestamp":1703197350000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/1\/279\/7240447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,8,10]]},"published-print":{"date-parts":[[2023,12,21]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad471","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,8,10]]}}}